Answers are grounded in this paper and cite their sources.
Carbon nanotubes (CNTs) and carbon nanofibers (CNFs) have been used for the first time to support ruthenium nanoparticles for the hydrogenation of p-chloronitrobenzene (p-CNB) to produce selectively p-chloroaniline. The preparation of well-dispersed ruthenium catalysts from the [Ru(3)(CO)(12)] precursor required activation of the purified supports by nitric acid oxidation. The supports, purified and functionalized, and the supported catalysts have been characterized by a range of techniques. The catalytic activity of these materials for the hydrogenation of p-CNB at 35 bar and 60 °C is shown to reach as high as 18 mol(p-CNB)g(Ru)(-1) h(-1), which is one order of magnitude higher than a commercial Ru/Al(2)O(3) catalyst. Selectivities between 92 and 94 % are systematically obtained, the major byproduct being aniline.
No takes yet. Share an insight, caveat, or question.
Oubenali et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: